Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Meta Platforms Inc (META) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Meta Platforms Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.74 (market cap $5.07B), while Meta Platforms Inc trades at $581.35 (market cap $1.53T). The key difference: Meta Platforms Inc is far larger — about 301.8× ACADIA Pharmaceuticals Inc.'s market cap, and Meta Platforms Inc pays a 0.35% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | META | |
|---|---|---|
Market Cap | $5.07B | $1.53T |
Sector | Health | Media |
52-Week High | $29.41 | $790.00 |
52-Week Low | $20.06 | $525.72 |
Enterprise Value | $4.19B | $1.55T |
Volume | — | 24,093,972 |
Dividend Yield | — | 0.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.39, up 0.62% on the day, with strong earnings momentum after Q2 2026 results beat expectations. The stock shows bullish technical signals from moving averages, though oscillators suggest potential overbought conditions. Revenue growth has been robust, rising from $517M in 2022 to $1.07B in 2025, with net income turning positive and margins expanding significantly. Recent news highlights FDA Fast Track designation for remlifanserin and raised 2026 revenue guidance.
Outlook remains positive driven by product sales growth and pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Analyst consensus is strongly bullish with a $33.89 price target, indicating ~15% upside. Investment appeal hinges on execution of commercial strategy and successful drug development.
META stock trades at $581.30, down 2.29% over 24 hours. The technical picture is neutral, with the price near key support at $580. Fundamentally, the company reported strong revenue of $200.97B for 2025 and a net income margin of 29.84%, though Q2 2026 EPS missed expectations. Recent news highlights the launch of the Muse Spark AI model and a significant legal ruling in Massachusetts.
The outlook is positive, supported by a strong analyst consensus (79% Buy) and a $761.95 price target. Key opportunities include AI monetization and revenue growth, while risks involve high capital expenditure, legal challenges, and competitive pressures in the social media and AI sectors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →
